AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01513499
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 24 IU single-dose administration
Trial: NCT00034541
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 225 mg/m2, infusion
Trial: NCT00034541
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30-minute AUC = 6, infusion.
Trial: NCT02902432
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
Trial: NCT00089388
Drug: cilengitide
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04545385
Drug: TEV-48574
RxNorm normalized name: Immunoglobulin G1 [de-449-lysine], anti-(human tumor necrosis factor superfamily protein TNFSF15) (human monoclonal TEV-48574 γ1-chain), disulfide with human monoclonal TEV-48574 λ-chain, dimer
DrugBank: Duvakitug (DB19444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous infusion
Trial: NCT00915278
Drug: PF-04605412
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
Trial: NCT00929669
Drug: pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pasireotide LAR 80 mg IM once a month
Trial: NCT01658839
Drug: Travoprost ophthalmic solution, 0.004% (new formulation)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost ophthalmic solution, 0.004%, new formulation
Trial: NCT02832713
Drug: Botulinum toxin A ( BoNT-A)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intra-articular injection of BoNT-A
Trial: NCT04256200
Drug: Dienogest 2 MG Oral Tablet
RxNorm normalized name: dienogest 2 MG Oral Tablet
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Deinogest (Visanne) 2mg/day, orally for 24 weeks versus combined OCP (Yasmin, 0.03mg
Trial: NCT04256200
Drug: Yasmin
RxNorm normalized name: Yasmin
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.03mg Ethinyl Estradiol and 3mg Drospirenone daily for 24 weeks
Trial: NCT00485823
Drug: Olanzapine Hydrochloride
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02197156
Drug: 20 mg HC-ER
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose
Trial: NCT02197156
Drug: 40 mg HC-ER
RxNorm normalized name: Casporyn HC
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose
Trial: NCT02346318
Drug: Compound Kushen Injection
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
Trial: NCT00070525
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03823625
Drug: Nivolumab plus Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
Trial: NCT03823625
Drug: Platinum-based chemotherapy plus Nivolumab
RxNorm normalized name: platinum
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days.
Trial: NCT00840125
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg tablet daily
Trial: NCT00840125
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
Trial: NCT02276677
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, intranasal
Trial: NCT02022917
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
Trial: NCT00669864
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (under the skin) injection, twice daily
Trial: NCT00669864
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, 1000 - 2000 mg daily
Trial: NCT00140517
Drug: sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00140517
Drug: chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00040378
Drug: alphatocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU daily
Trial: NCT00040378
Drug: Selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mcg daily
Trial: NCT00040378
Drug: Placebo replacement for vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 placebo pill daily
Trial: NCT00040378
Drug: Placebo replacement for Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo pill daily
Trial: NCT01217801
Drug: Ondansetron (ODFS)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
Trial: NCT01217801
Drug: Ondansetron (ODT)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
Trial: NCT00740571
Drug: amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: strategy in which the patient starts with amitriptyline, during 8 weeks
Trial: NCT01369433
Drug: Tivozanib + paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
Trial: NCT01369433
Drug: Tivozanib + temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
Trial: NCT01369433
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
Trial: NCT01369433
Drug: Tivozanib (AV-951)
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
Trial: NCT01369433
Drug: Tivo
RxNorm normalized name: Tivorbex
DrugBank: Egaptivon pegol (DB05202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
Trial: NCT02421042
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
Trial: NCT03163966
Drug: CR6086
RxNorm normalized name: CR6086
DrugBank: CR6086 (DB16111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral CR6086 capsules
Trial: NCT00740571
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Strategy in which patient starts with pregabalin
Trial: NCT03805399
Drug: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
Trial: NCT03805399
Drug: anti PD-1 with nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
Trial: NCT04085666
Drug: CDX 6114
RxNorm normalized name: CDX
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
Trial: NCT03805399
Drug: PARP inhibitor included therapy
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
Trial: NCT03805399
Drug: mTOR inhibitor with nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
Trial: NCT04057365
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
Trial: NCT04057365
Drug: DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
Trial: NCT02423759
Drug: ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
Trial: NCT02423759
Drug: ciprofloxacin and gentamycine
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
Trial: NCT02423759
Drug: culture based chemoprophylaxis
RxNorm normalized name: casein, emmental cultured
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
Trial: NCT00744809
Drug: TMC278; Moxifloxacin; Efavirenz
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02651441
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
Trial: NCT02651441
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Trial: NCT01682031
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02819817
Drug: Aloe Vera Gel
RxNorm normalized name: ALOE VERA GEL
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
Trial: NCT00324155
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression
Trial: NCT00324155
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Trial: NCT01414296
Drug: PSMA ADC
RxNorm normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA ADC administered IV
Trial: NCT03918798
Drug: Chloroprocaine 1% Injectable Solution
RxNorm normalized name: chloroprocaine 1% injectable solution
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Trial: NCT03918798
Drug: Chloroprocaine 2% Injectable Solution
RxNorm normalized name: chloroprocaine 2% injectable solution
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Trial: NCT03314025
Drug: Tamsulosin Hydrochloride 0.4 MG
RxNorm normalized name: tamsulosin hydrochloride 0.4 MG
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
Trial: NCT01986582
Drug: Oxymetazoline
RxNorm normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal application
Trial: NCT00009997
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00009997
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049569
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00049569
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00049569
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00049569
Drug: pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00049569
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00049569
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00049569
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT01698788
Drug: Dexamethasone Drug delivery system (Ozurdex)
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a sustained release intravitreal implant containing 700µg dexamethasone
Trial: NCT02993367
Drug: Butylphthalide Soft Capsules
RxNorm normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
Trial: NCT02993367
Drug: Placebo Butylphthalide Soft Capsules
RxNorm normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01756703
Drug: MT-3995 Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MT-3995 Low dose for 8 weeks
Trial: NCT01756703
Drug: MT-3995 High
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-3995 High dose for 8 weeks
Trial: NCT01070680
Drug: Precedex
RxNorm normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mkg/ml,continuous infusion at rate 0.7 µg/kg/h
Trial: NCT01070680
Drug: sodium chlorid 0,9%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion
Trial: NCT00384631
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
Trial: NCT00315549
Drug: Penicillin
RxNorm normalized name: Penicillin
DrugBank: Nafcillin (DB00607)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002791
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002791
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002791
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00254085
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03325439
Drug: Brivaracetam (BRV) intravenous (iv)
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment.
Trial: NCT04094870
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily SSRI (Sertraline 25mg)
Trial: NCT03325439
Drug: Brivaracetam (BRV) oral
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period